Cystoscopy Revisited as the Gold Standard for Detecting Bladder Cancer Recurrence: Diagnostic Review Bias in the Randomized, Prospective CEFUB Trial

Journal of Urology

Volumn 183, Issue 1, 2010, Pages 76-80

  van der Aa, Madelon N M ^a   Steyerberg, Ewout W ^a   Bangma, Chris ^a   van Rhijn, Bas W G ^a   Zwarthoff, Ellen C ^a   van der Kwast, Theo H ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

bias (epidemiology); carcinoma; cystoscopy; urinary bladder; urothelium

Indexed keywords

AGED; ARTICLE; BLADDER CANCER; BLADDER SURGERY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CHI SQUARE TEST; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTOSCOPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE MARKER; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TRANSURETHRAL RESECTION; URINALYSIS; UROLOGY;

AGED; BIAS (EPIDEMIOLOGY); CARCINOMA, TRANSITIONAL CELL; CYSTOSCOPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MICROSATELLITE REPEATS; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; URINARY BLADDER NEOPLASMS;

EID: 71249136737     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2009.08.150     Document Type: Article

References (20)

1. Herr H.W. Max Nitze, the cystoscope and urology. J Urol 176 (2006) 1313
2. Botteman M.F., Pashos C.L., Redaelli A., et al. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 21 (2003) 1315
3. Wright M.P., and Jones D.J. Surveillance for bladder cancer: the management of 4.8 million people. South-west Urologists. BJU Int 85 (2000) 431
4. Mariappan P., and Smith G. A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database. J Urol 173 (2005) 1108
5. Riley G.F., Potosky A.L., Lubitz J.D., et al. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care 33 (1995) 828
6. van Rhijn B.W., Lurkin I., Kirkels W.J., et al. Microsatellite analysis-DNA test in urine competes with cystoscopy in follow-up of superficial bladder carcinoma: a phase II trial. Cancer 92 (2001) 768
7. Steiner G., Schoenberg M.P., Linn J.F., et al. Detection of bladder cancer recurrence by microsatellite analysis of urine. Nat Med 3 (1997) 621
8. Seripa D., Parrella P., Gallucci M., et al. Sensitive detection of transitional cell carcinoma of the bladder by microsatellite analysis of cells exfoliated in urine. Int J Cancer 95 (2001) 364
9. Mao L., Schoenberg M.P., Scicchitano M., et al. Molecular detection of primary bladder cancer by microsatellite analysis. Science 271 (1996) 659
10. Van der Aa M., Zwarthoff E.C., Steyerberg E.W., et al. Microsatellite Analysis of voided urine samples for surveillance of low grade non-muscle invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (CEFUB). Eur Urol 55 (2009) 659
11. Oakes D., and Cui L. On Semiparametric inference for modulated renewal processes. Biometrika 81 (1994) 83
12. Bossuyt P.M., Reitsma J.B., Bruns D.E., et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann Intern Med 138 (2003) W1
13. Van der Aa M.N., Steyerberg E.W., Sen E.F., et al. Patients' perceived burden of cystoscopic and urinary surveillance of bladder cancer: a randomized comparison. BJU Int 101 (2008) 1106
14. Schmidbauer J., Witjes F., Schmeller N., et al. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol 171 (2004) 135
15. Jocham D., Witjes F., Wagner S., et al. Improved detection and treatment of bladder cancer using Hexvix imaging: a prospective phase III multi-center study. J Urol 174 (2005) 862
16. Nguyen C.T., Babineau D.C., and Jones J.S. Impact of urologic resident training on patient pain and morbidity associated with office-based cystoscopy. Urology 71 (2008) 782
17. Soloway M.S., Bruck D.S., and Kim S.S. Expectant management of small, recurrent, noninvasive papillary bladder tumors. J Urol 170 (2003) 438
18. Pruthi R.S., Baldwin N., and Bhalani V. Conservative management of low risk superficial bladder tumors. J Urol 179 (2008) 87
19. Grossman H.B., Gomella L., Fradet Y., et al. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol 178 (2007) 62
20. Hungerhuber E., Stepp H., Kriegmair M., et al. Seven years' experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder. Urology 69 (2007) 260